secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001437749-23-021186
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Auditor MHM declines re-election as SAB Biotherapeutics' independent auditor; going concern noted
--------------------------------------------------------------------------------

- MHM notified SAB Biotherapeutics on July 25, 2023 it will not stand for re-election as auditor for FY 2023.
- MHM to cease as auditor by earlier of new firm engagement, Q2 2023 10-Q filing, or August 21, 2023.
- MHM's audit reports for 2021-2022 included a going concern explanatory paragraph and a material weakness in internal controls leading to a restatement.
- Company is in process of selecting a new independent registered public accounting firm; no successor named yet.
- MHM furnished a letter to the SEC (Exhibit 16.1) agreeing with the company's statements in this 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923021186/0001437749-23-021186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923021186/sabs20230728_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-021186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer